Top Markets
Coin of the day
Lumosa Therapeutics Co., Ltd. Lumosa Therapeutics Co., Ltd.

Lumosa Therapeutics Co., Ltd.

6535
Rank in Stocks #14760
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company,... Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
Share Price
$2.35
Market Cap
$394.12M
Change (1 day)
-1.07%
Change (1 year)
-64.75%
Country
TW
Trade Lumosa Therapeutics Co., Ltd. (6535)

Category

P/B ratio for Lumosa Therapeutics Co., Ltd. (6535)
P/B ratio as of 2026 TTM: 0
According to Lumosa Therapeutics Co., Ltd. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Lumosa Therapeutics Co., Ltd. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.828 -
US
7.5116 -
NL
3.9942 -
AU
8.2199 -
US
- -
CH